ETF Holdings Breakdown of MGNX

MGNX institutional holdings

The adjusted close for MGNX on 2025-11-11 was 1.52

The following institutional investment holdings of MGNX have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	39,640	USD 60,253 5.9%	1.52
2025-11-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	39,640	USD 60,253 5.9%	1.52
Total =		79,280	USD 120,506

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with MGNX

MacroGenics (NASDAQ:MGNX) Now Covered by Analysts at Barclays

Research analysts at Barclays initiated coverage on shares of MacroGenics (NASDAQ:MGNX – Get Free Report) in a report issued on Wednesday, Marketbeat.com reports. The firm set an “overweight” rating and a $3.00 price target on the biopharmaceutical company’s stock. Barclays‘s price target would suggest a potential upside of 73.41% from the stock’s previous close. Several […] - 2025-09-19 02:50:55

MacroGenics (NASDAQ:MGNX) Upgraded by Barclays to Strong-Buy Rating

Barclays upgraded shares of MacroGenics (NASDAQ:MGNX – Free Report) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports. Several other research firms also recently weighed in on MGNX. B. Riley dropped their target price on shares of MacroGenics from $5.00 to $3.00 and set a “neutral” rating for the company in a […] - 2025-09-19 02:02:52

MacroGenics, Inc. (NASDAQ:MGNX) Receives $3.60 Consensus Target Price from Analysts

Shares of MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) have been given a consensus rating of “Moderate Buy” by the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy […] - 2025-09-15 02:12:59

MacroGenics (NASDAQ:MGNX) Stock Price Crosses Below 200 Day Moving Average – Should You Sell?

Shares of MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.68 and traded as low as $1.64. MacroGenics shares last traded at $1.64, with a volume of 911,663 shares changing hands. Wall Street Analyst Weigh In MGNX […] - 2025-08-26 05:18:57

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to […] - 2025-08-18 05:23:02

MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of “Hold” from Analysts

MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) has been assigned a consensus recommendation of “Hold” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. […] - 2025-07-24 05:11:01

MacroGenics (NASDAQ:MGNX) Raised to Hold at Wall Street Zen

MacroGenics (NASDAQ:MGNX – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday. Several other analysts have also weighed in on MGNX. Barclays reaffirmed an “overweight” rating and issued a $3.00 price objective (down […] - 2025-07-14 03:40:47

MacroGenics, Inc. (NASDAQ:MGNX) Receives $5.71 Average PT from Analysts

Shares of MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) have received an average recommendation of “Hold” from the ten brokerages that are currently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to […] - 2025-07-02 02:22:52

MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Analysts

Shares of MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) have earned an average recommendation of “Hold” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to […] - 2025-06-09 03:40:51

Millennium Management LLC Sells 671,179 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

Millennium Management LLC reduced its stake in MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 19.0% during the fourth quarter, HoldingsChannel reports. The fund owned 2,864,721 shares of the biopharmaceutical company’s stock after selling 671,179 shares during the period. Millennium Management LLC’s holdings in MacroGenics were worth $9,310,000 as of its most recent SEC filing. Several […] - 2025-05-26 04:42:51

Dimensional Fund Advisors LP Has $2.33 Million Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX)

Dimensional Fund Advisors LP decreased its position in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 18.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 717,288 shares of the biopharmaceutical company’s stock after selling 165,372 shares during the quarter. Dimensional Fund Advisors […] - 2025-05-15 04:31:10

Price T Rowe Associates Inc. MD Lowers Stake in MacroGenics, Inc. (NASDAQ:MGNX)

Price T Rowe Associates Inc. MD decreased its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 61.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 485,987 shares of the biopharmaceutical company’s stock after selling 768,249 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in MacroGenics were worth $1,581,000 […] - 2025-05-09 06:25:03

Marshall Wace LLP Raises Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)

Marshall Wace LLP grew its holdings in MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 3.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 393,766 shares of the biopharmaceutical company’s stock after acquiring an additional 12,250 shares during the period. Marshall Wace […] - 2025-04-30 05:41:02

XTX Topco Ltd Acquires 55,564 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

XTX Topco Ltd grew its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 497.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 66,742 shares of the biopharmaceutical company’s stock after acquiring an additional 55,564 shares during the […] - 2025-04-28 06:20:59

JPMorgan Chase & Co. Increases Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)

JPMorgan Chase & Co. increased its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) by 68.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 546,807 shares of the biopharmaceutical company’s stock after buying an additional 221,905 shares during the period. JPMorgan Chase & Co.’s holdings in MacroGenics were worth $1,777,000 as […] - 2025-04-25 04:18:49

HC Wainwright Lowers MacroGenics (NASDAQ:MGNX) Price Target to $2.00

MacroGenics (NASDAQ:MGNX – Free Report) had its price objective cut by HC Wainwright from $4.00 to $2.00 in a research note released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. Separately, StockNews.com downgraded MacroGenics from a “buy” rating to a “hold” rating in a research report on Friday, […] - 2025-03-26 04:52:44

MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Average PT from Analysts

MacroGenics, Inc. (NASDAQ:MGNX – Get Free Report) has been given an average recommendation of “Hold” by the eleven analysts that are covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. […] - 2025-03-26 03:53:00

Back to Listing

Disclaimer